Vir Biotechnology (VIR) Scheduled to Post Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR) is set to post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Vir Biotechnology to post earnings of ($0.99) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.28. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The company had revenue of $16.80 million during the quarter, compared to analyst estimates of $11.18 million. During the same period in the prior year, the business posted ($0.76) EPS. The firm’s revenue was down 66.0% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Down 1.1 %

NASDAQ:VIR opened at $8.04 on Thursday. The company has a fifty day moving average of $10.03 and a 200 day moving average of $9.60. Vir Biotechnology has a 52 week low of $7.72 and a 52 week high of $27.48. The firm has a market capitalization of $1.08 billion, a P/E ratio of -1.75 and a beta of 0.41.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Friday, March 15th. JPMorgan Chase & Co. upped their price objective on shares of Vir Biotechnology from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

Insider Buying and Selling

In related news, EVP Phillip Pang sold 3,321 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $10.24, for a total value of $34,007.04. Following the transaction, the executive vice president now owns 264,679 shares of the company’s stock, valued at $2,710,312.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Vir Biotechnology news, CFO Sung Lee sold 6,008 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $9.89, for a total transaction of $59,419.12. Following the sale, the chief financial officer now owns 100,492 shares in the company, valued at approximately $993,865.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Phillip Pang sold 3,321 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $10.24, for a total transaction of $34,007.04. Following the sale, the executive vice president now owns 264,679 shares in the company, valued at approximately $2,710,312.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,831 shares of company stock valued at $1,525,844. 18.10% of the stock is owned by insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.